- Home
- EPC vs CVAC Comparison
EPC vs CVAC Comparison
Compare EPC & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPC
- CVAC
- Stock Information
- Founded
- EPC 1999
- CVAC 2000
- Country
- EPC United States
- CVAC Germany
- Employees
- EPC N/A
- CVAC N/A
- Industry
- EPC Package Goods/Cosmetics
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- EPC Consumer Discretionary
- CVAC Health Care
- Exchange
- EPC Nasdaq
- CVAC Nasdaq
- Market Cap
- EPC 1.4B
- CVAC 1.2B
- IPO Year
- EPC 2000
- CVAC 2020
- Fundamental
- Price
- EPC $20.25
- CVAC $5.41
- Analyst Decision
- EPC Buy
- CVAC Hold
- Analyst Count
- EPC 7
- CVAC 3
- Target Price
- EPC $28.29
- CVAC $6.83
- AVG Volume (30 Days)
- EPC 763.5K
- CVAC 404.4K
- Earning Date
- EPC 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- EPC 2.96%
- CVAC N/A
- EPS Growth
- EPC N/A
- CVAC N/A
- EPS
- EPC 1.34
- CVAC 1.01
- Revenue
- EPC $2,203,900,000.00
- CVAC $599,540,810.00
- Revenue This Year
- EPC N/A
- CVAC N/A
- Revenue Next Year
- EPC $2.32
- CVAC $23.83
- P/E Ratio
- EPC $15.12
- CVAC $5.40
- Revenue Growth
- EPC N/A
- CVAC 675.15
- 52 Week Low
- EPC $19.13
- CVAC $2.37
- 52 Week High
- EPC $38.45
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- EPC 39.91
- CVAC 53.41
- Support Level
- EPC $19.87
- CVAC $5.33
- Resistance Level
- EPC $21.05
- CVAC $5.45
- Average True Range (ATR)
- EPC 0.60
- CVAC 0.03
- MACD
- EPC 0.09
- CVAC 0.01
- Stochastic Oscillator
- EPC 54.44
- CVAC 66.10
About EPC Edgewell Personal Care Company
Edgewell Personal Care Co is a personal-care company. The operating segments of the company include Wet Shave, Sun and Skin Care and Feminine Care. Some of the brands offered by the company include Edge, Skintimate, Personna, Schick, Carefree, Playtex, Banana Boat and Hawaiian Tropic. It derives a majority of its revenue from the United States.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.